Cardiac Energetics and Function in Normal Human Ageing

NCT01504828 | Completed

• 2 other identifiers: BH11145495309
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 1

Brief Summary

Normal aging is characterized by altered cardiovascular function. Our preliminary data with MR imaging and spectroscopy in normal subjects without cardiovascular disease or hypertension show that age-related cardiac dysfunction is characterized initially by impaired relaxation of the heart (40 - 60 years), and then at \> 60 years altered contraction and impaired myocardial energetics. For the first time, the investigators will test whether the functional and energetic effects of normal aging can be reversed by acutely reducing stiffness of peripheral blood vessels using an ACE inhibitor. This will potentially have important insights into how normal aging affects the heart, and how potential treatments could be used to attenuate this process.

Conditions

Left Ventricular Function Systolic Dysfunction; Left Ventricular Function Diastolic Dysfunction; Ageing

Keywords

Energy Metabolism; Ageing; left ventricle; energetics; function

Outcome Measures

Primary Outcomes (3)

• Vascular Stiffness

  There are 3 principal measures of vascular stiffness, and these are central pulse pressure, central systolic pressure, and the augmentation index. These are correlated against the 3 principal measures of left ventricular function and energetics that are known to change with age: torsion to shortening ratio, early to late diastolic filling ratio, and the ratio of phosphocreatine to adenosine triphosphate (listed as separate Primary Outcome Measures).

  2 Hours - Acute study with no follow-up

• Left Ventricular Energetics

  Left ventricular energetics is measured as the ratio of phosphocreatine to adenosine triphosphate

  2 hours - Acute Study, no follow-up

• Left Ventricular Function

  Left ventricular function is measured with the 2 parameters that are known to change with age: ratio of early to late diastolic filling, and ratio of torsion to shortening ratio.

  2 hours - Acute Study, no follow-up

Secondary Outcomes (1)

• Effects of ACE inhibitor on left ventricular energetics and function in those subjects aged 40 and over

  6 hours - Acute study, no follow-up

Study Arms (1)

Ramipril

EXPERIMENTAL

Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function

Drug: Ramipril

Interventions

Ramipril DRUG

Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics

Ramipril

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects between the ages of 20 and 80 years

You may not qualify if:

• Any cardiovascular condition including hypertension, or on any cardiovascular therapy.
• Blood Pressure \> 150 mmHg systolic, and/or \> 90 mmHg diastolic
• Claustrophobia
• Implanted metal prosthesis
• Chronic renal failure requiring dialysis
• Diabetes mellitus.

Sponsors & Collaborators

• Newcastle-upon-Tyne Hospitals NHS Trust: lead

Study Sites (1)

Campus for Ageing and Vitality

Newcastle upon Tyne, NE4 6BE, United Kingdom

Location

Related Publications (2)

• Hollingsworth KG, Blamire AM, Keavney BD, Macgowan GA. Left ventricular torsion, energetics, and diastolic function in normal human aging. Am J Physiol Heart Circ Physiol. 2012 Feb 15;302(4):H885-92. doi: 10.1152/ajpheart.00985.2011. Epub 2011 Dec 16.

  PMID: 22180656 BACKGROUND

• Parikh JD, Hollingsworth KG, Kunadian V, Blamire A, MacGowan GA. Measurement of pulse wave velocity in normal ageing: comparison of Vicorder and magnetic resonance phase contrast imaging. BMC Cardiovasc Disord. 2016 Feb 19;16:50. doi: 10.1186/s12872-016-0224-4.

  PMID: 26892669 DERIVED

MeSH Terms

Interventions

Ramipril

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Guy A MacGowan, MD

  Freeman Hospital, Newcastle upon Tyne and Newcastle University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 21, 2011
• First Posted: January 5, 2012
• Study Start: July 1, 2012
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: March 30, 2017

Record last verified: 2017-03

Locations

GB (1)